N-terminal pro-B-type natriuretic peptide: A measure of significant patent ductus arteriosus

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 93, Issue 4, 2008, Pages

  Farombi Oghuvbu, I ^a   Matthews, T ^a   Mayne, P D ^a   Guerin, H ^a   Corcoran, J D ^a  

^a ROTUNDA HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COLOR ULTRASOUND FLOWMETRY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE SEVERITY; EVALUATION; FEMALE; HEART LEFT RIGHT SHUNT; HUMAN; MALE; NEWBORN; NEWBORN SEPSIS; PATENT DUCTUS ARTERIOSUS; PREMATURITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

BIOLOGICAL MARKERS; DUCTUS ARTERIOSUS, PATENT; FEMALE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 47849126560     PISSN: 13592998     EISSN: 14682052     Source Type: Journal    
DOI: 10.1136/adc.2007.120691     Document Type: Article

References (30)

1. Gorenjak M. Natriuretic peptides in assessment of ventricular dysfunction. eJIFCC Vol 14 No 2. Available at http://www.ifcc.org/ejifcc/ vol14no2/1402062003011n.htm (accessed 19 February 2008).
2. Maisel AS, Koon J, Krishnaswamy P, et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J 2001;141:367-74.
3. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-7.
4. Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 2001;37:379-85.
5. Witthaut R. Science review: Natriuretic peptides in critical illness. Crit Care 2004;8:342-9.
6. Reynolds EW, Ellington JG, Vranicar M, et al. Brain-type natriuretic peptide in the diagnosis and management of persistent pulmonary hypertension of the newborn. Pediatrics 2004;114:1297-304.
7. Mir TS, Marohn S, Laer S, et al. Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure. Pediatrics 2002;110:e76.
8. Holstrom H, Omland T. Natriuretic peptides as markers of patent ductus arteriosus in preterm infants. Clin Sci (Lond) 2002;103:79-80.
9. Pesonen E. Role of natriuretic hormones in the diagnosis of patent ductus arteriosus in preterm infants. Acta Paediatr 2001;90:363- 5.
10. Puddy VF, Amirmansour C, Williams AF, et al. Plasma natriuretic peptide as a predictor of haemodynamically significant patent ductus arteriosus in preterm infants. Clin Sci (Lond) 2002;103:75-7.
11. Choi BM, Lee KH, Eun BL, et al. Utility of rapid B-type natriuretic peptide assay for diagnosis of symptomatic patent ductus arteriosus in preterm infants. Pediatrics 2005;115:e255-61.
12. Walther FJ, Benders MJ, Leighton JO. Persistent pulmonary hypertension in premature infants with severe respiratory distress syndrome. Pediatrics 1992;90:899-904.
13. Kluckow M, Evans N. High pulmonary blood flow, the duct and pulmonary hemorrhage. J Pediatr 2000;137:68-72.
14. Evans N. Diagnosis of patent ductus arteriosus in the preterm newborn. Arch Dis Child 1993;68:58-61.
15. Skelton R, Evans N, Smythe J. A blinded comparison of clinical and echochardiographic evaluation of the preterm infant for patent ductus arteriosus. J Paediatr Child Health 1994;30:406-11.
16. Skinner J. Diagnosis of patent ductus arteriosus. Semin Neonatol 2001;6:49-61.
17. Tammela O, Ojala R, Iivainen T, et al. Short vs. prolonged indomethacin therapy for patent ductus arteriosus in preterm infants. J Pediatr 1999;134:552-7.
18. Van Overmeire B, Follens I, Hartmann S, et al. Treatment of patent ductus arteriosus with ibuprofen. Arch Dis Child 1997;76:179-84.
19. Hammerman C, Aramburo MJ. Prolonged indomethacin therapy for the prevention of recurrences of patent ductus arteriosus. J Pediatr 1990;117:771-6.
20. Evans N, Moorcraft J. Effect of patency of the ductus arteriosus on blood pressure in very preterm infants. Arch Dis Child 1992;67:1169-73.
21. Kluckow M, Evans N. Low superior vena cava flow and intraventricular haemorrhage in preterm infants. Arch Dis Child Fetal Neonatal Ed 2000;82:F188-94.
22. Andersson S, Tikkanen L, Pesonen E, et al. Atrial natriuretic peptide in patent ductus arteriosus. Pediatr Res 1987;21:396-8.
23. Rascher W, Seyberth H. Atrial natriuretic peptide and patent ductus arteriosus in preterm infants. Arch Dis Child 1987;62:1165- 7.
24. Holmstrom H, Hall C, Thaulow E. Plasma levels of natriuretic peptides and hemodynamic assessment of patent ductus arteriosus in preterm infants. Acta Paediatr 2001;90:184-9.
25. Fried I, Bar-Oz B, Algur N, et al. Comparison of N-termmal pro-B-type natriuretic peptide levels in critically ill children with sepsis versus acute left ventricular dysfunction. Pediatrics 2006;118:e1165-8.
26. Tanaka T, Kanda T, Takahashi T, et al. Interleukin-6- induced reciprocal expression of SERCA and natriuretic peptides mRNA in cultured rat ventricular myocytes. J Int Med Res 2004;32:57-61.
27. Witthaut R, Busch C, Fraunberger P, et al. Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: impact of interleukin-6 and sepsis-associated left ventricular dysfunction. Intensive Care Med 2003;29:1696-702.
28. Brueckmann M, Huhle G, Lang S, et al. Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis. Circulation 2005;112:527-34.
29. Ma KK, Ogawa T, de Bold AJ. Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by proinflammatory cytokines and by conditioned medium derived from mixed lymphocyte reaction via p38 MAP kinase. J Mol Cell Cardiol 2004;36:505-13.
30. Clerico A, Recchia FA, Passino C, et al. Cardiac endocrine function is an essential component function of the homeostatic regulation network: physiological and clinical implications. Am J Physiol Heart Circ Physiol 2006;290:H17-29.